<DOC>
	<DOCNO>NCT01949090</DOCNO>
	<brief_summary>The purpose placebo control study evaluate safety immunogenicity different formulation GSK Biologicals H7N1 influenza vaccine subject 65 year age old . The study evaluate safety related event antibody immune response different formulation study vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Study Different Formulations GlaxoSmithKline ( GSK ) Biologicals H7N1 Influenza Vaccine Administered Adults 65 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female adult 65 year age old time first study vaccination . Written inform consent obtain subject . Subjects investigator believe comply requirement protocol . Stable health status , establish medical history physical exam , define absence health event satisfy definition serious adverse event , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within 1 month prior enrollment . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Presence evidence neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence evidence substance abuse . Diagnosed cancer , treatment cancer within three year . Persons history cancer diseasefree without treatment three year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision except eligible , histologic type skin cancer exclusionary . Women diseasefree three year treatment breast cancer receive longterm prophylaxis eligible . Diagnosed excessive daytime sleepiness ( unintended sleep episode day present almost daily least one month ) , narcolepsy ; history narcolepsy subject 's parent , sibling child . Presence temperature ≥ 38.0ºC ( ≥100.4ºF ) , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid within 30 day prior first dose study vaccine/placebo , cytotoxic , immunosuppressive immunemodifying drug within 6 month first study vaccine/placebo dose . Topical , intraarticularly inject , inhaled glucocorticoid , topical calcineurin inhibitor imiquimod allow . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder Guillain Barré Syndrome within 42 day receipt prior seasonal pandemic influenza vaccine . Administration inactive vaccine within 14 day live attenuated vaccine within 30 day first dose study vaccine/placebo . Planned administration vaccine study vaccine/placebo blood sample Day 42 visit . Previous administration H7 vaccine physicianconfirmed H7 disease . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine/placebo , plan use study period . Receipt immunoglobulins and/or blood product within 90 day first dose study vaccine/placebo , plan administration product study period . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine include history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>H7N1</keyword>
	<keyword>AS03 adjuvant</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza</keyword>
	<keyword>Adults</keyword>
	<keyword>Elderly adult</keyword>
</DOC>